Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
about
Gene therapy for peripheral arterial diseaseTherapeutic angiogenesis for critical limb ischaemia.Critical limb ischemia: current approach and future directions.Lower extremity amputation in peripheral artery disease: improving patient outcomes.Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patientsBone marrow aspirate injection for treatment of critical limb ischemia with comparison to patients undergoing high-risk bypass grafts.Validation of the Society for Vascular Surgery's objective performance goals for critical limb ischemia in everyday vascular surgery practice.The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial designLPS-Stimulated Human Skin-Derived Stem Cells Enhance Neo-Vascularization during Dermal RegenerationFabrication and characterization of injectable hydrogels derived from decellularized skeletal and cardiac muscle.Elevated Blood Urea Nitrogen is Associated With Critical Limb Ischemia in Peripheral Arterial Disease PatientsA randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.Critical limb ischemia: cell and molecular therapies for limb salvageModulating the vascular response to limb ischemia: angiogenic and cell therapies.From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's Ixmyelocel-T.Therapeutic angiogenesis in critical limb ischemia.Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis.Medical management of critical limb ischaemia: where do we stand today?Clinical effectiveness of gene therapy on critical limb ischemia: a meta-analysis of 5 randomized controlled clinical trials.Beperminogene perplasmid for the treatment of critical limb ischemia.Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.What can I do with a patient with diabetes and critically impaired limb perfusion who cannot be revascularized?Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial DiseaseLimb ischemia: cardiovascular diagnosis and management from head to toe.Current Phase II drugs under investigation for the treatment of limb ischemia.Stem Cell Smart Technology, where are we now and how far we have to go?Current therapies and investigational drugs for peripheral arterial disease.Growth factors for angiogenesis in peripheral arterial disease.Gene-based therapies in patients with critical limb ischemia.Biochemical and Biophysical Cues in Matrix Design for Chronic and Diabetic Wound Treatment.Trimodal rescue of hind limb ischemia with growth factors, cells, and nanocarriers: fundamentals to clinical trials.An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.Gene therapy for neuropathic pain induced by spared nerve injury with naked plasmid encoding hepatocyte growth factor.Management of infrapopliteal peripheral arterial occlusive disease.Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science.
P2860
Q24186712-0987C33B-AD27-4D24-B1AF-2A0B5962CC81Q30456666-3F5F4251-A02C-4F98-B931-4715E10BA60AQ30458139-83DD610F-EC23-4B69-B373-00CFC9CE8E9AQ33934939-E1C62F7B-A84C-41E7-8930-778F08818059Q34607040-DA75B203-01E5-43EF-8663-1BE4EA0EBE1AQ34812035-5410BDB2-9FC6-4E6A-AA80-64FEC32C62B1Q35085840-EEDC1547-429C-4C1B-B77A-E10CB33A4A4DQ35318581-AC481E9F-5684-4DB0-BF13-2F2CCA5489D5Q35840611-BA9EEC53-AFEB-4473-918D-34CC067CF56FQ35920945-7008A279-7736-4F5A-BD93-0DC98801DEE4Q36194559-CEB8C493-0256-4007-8A08-3FA71820CC03Q36546561-139F21AC-52F4-4E9E-892F-A804CC289955Q36547498-FD73E1C0-7600-4F52-9957-2D536F8CE6ACQ36908997-99DB82CF-3F93-4B41-B640-88C4DEB339B6Q36923569-A1F2E085-8C5D-4ED9-AD9E-6F003BDB4B62Q37142832-AC072CB9-8AB9-424B-B66F-AAE9003C868FQ38088776-2ECEF06B-70CF-4B0E-A09F-6925312C654BQ38116561-4A036F82-0DE0-4C20-834A-B1A0C17D05C4Q38222060-C13EFEA9-27E6-4D00-9EFC-72FEEAE372E3Q38246211-CB328E6C-49F5-48F0-AC59-21EB2997C636Q38255164-B0E74A93-F75A-4704-BFF1-A3E43017D2CDQ38261175-436443FE-F5B9-4BCC-9F36-6574A99ACFCCQ38382866-13DBE97B-D7BA-4F53-9A8C-B53AE85F1C31Q38511050-644D0ABF-687D-428D-B8F7-FC38F9C5B68FQ38571123-E65B92FF-E5E8-4B0C-A926-3059020BD3FCQ38637333-CEE77606-A112-4277-817B-EABE41DD8DB2Q38657444-154F4FF8-75EA-46CE-92E1-1284ED663DB1Q38736561-117CF3E5-D3EC-494F-8850-3F7409B0C43FQ38764506-D157C6F2-53DA-4B2C-91D3-7B34D18B344DQ38894255-5417D98E-E1A6-4D00-A5A0-677739A65408Q39240834-B4729D94-03B6-4AC8-858A-FD81E4028FA3Q42088207-7185BA4F-5D2A-4E93-9610-16906925F4FFQ45873482-3564A44D-AAE7-4E13-9251-B7B8DDC0A7A4Q46903055-5F22684F-13EF-454E-ADFF-B6460C852F93Q50072297-7B96FEBA-D947-468E-91B5-E3E899D55764
P2860
Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@ast
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@en
type
label
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@ast
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@en
prefLabel
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@ast
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@en
P2093
P2860
P1476
Safety and efficacy of patient ...... results of the HGF-0205 trial.
@en
P2093
Brian H Annex
Elaine K Moen
Farrell O Mendelsohn
HGF-0205 Trial Investigators
Phillip Goodney
Richard J Powell
P2860
P304
P356
10.1016/J.JVS.2010.07.044
P577
2010-12-01T00:00:00Z